BTN3A1 and cervical cancer: This study provides proof‐of‐concept evidence showing that through direct killing, antigen presentation, and competitively binding to BTN3A1, Vγ9Vδ2 T cells amplified from cervical cancer (CC) patients can synergize with αβ T cells to exert anti‐CC function both in vitro and in vivo.